Skip to main content

Table 2 Clinical outcomes

From: Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results

Clinical outcome Pre-procedure 1-Year* 2-Years*
ABI 0.63 ± 0.18 (980) 0.86 ± 0.17 (826) 0.85 ± 0.18 (646)
Rutherford classa    
 0 1.0 (10) 54.1% (429) 52.2% (358)
 1 7.3% (74) 23.6% (187) 27.8% (191)
 2 26.6% (271) 11.0% (87) 11.8% (81)
 3 43.8% (447) 5.5% (44) 4.7% (32)
 4 10.3% (105) 2.8% (22) 1.6% (11)
 5 9.7% (99) 2.5% (20) 1.3% (9)
 6 1.4% (14) 0.5% (4) 0.6% (4)
  1. Values are mean ± SD or % (n)
  2. ABI ankle brachial index
  3. aPre-procedure Rutherford class was obtained for 1020 lesions, 1-year Rutherford scores were obtained for 793 lesions, and 2-year Rutherford scores were obtained for 686 lesions
  4. *Statistically significant compared to pre-procedure, p < 0.01